Abstract
Background: Pancreatic cancer has a poor prognosis with 5 year survival rates that do not exceed 5%. Drug concentrations for systemically administered cytostatics in most cases do not reach levels that affect the tumor and can not be increased due to toxic side effects.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
